Thermo Fisher Scientific Inc
NYSE:TMO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Medtronic PLC
NYSE:MDT
|
IE |
Thermo Fisher Scientific Inc
Total Liabilities & Equity
Thermo Fisher Scientific Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Liabilities & Equity
$110.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Liabilities & Equity
$83.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Waters Corp
NYSE:WAT
|
Total Liabilities & Equity
$5.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Total Liabilities & Equity
$3.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Liabilities & Equity
$12.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Liabilities & Equity
$29.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
23%
|
|
Thermo Fisher Scientific Inc
Glance View
Thermo Fisher Scientific Inc. stands as a towering entity in the life sciences industry, intricately weaving together science, technology, and business to drive scientific progress and innovation. Founded through a merger of Thermo Electron and Fisher Scientific in 2006, the company has grown exponentially to become a formidable partner for researchers, academicians, and clinicians worldwide. Its business model is built around a broad portfolio of offerings, including laboratory instruments, analytical tools, and consumables, which are crucial for research and quality control. By emphasizing research and development, Thermo Fisher has consistently advanced its technologies, ensuring that its solutions remain indispensable to ventures in pharmaceuticals, biotechnology, and diagnostics. The strategic acquisition of complementary businesses has been a key facet of Thermo Fisher’s growth, fortifying its position across various scientific fields. In essence, the company thrives on understanding the increasingly complex demands of the scientific community. It generates revenue by capitalizing on its diverse product lineup, subscription-based services, and personalized solutions that cater to specific client needs—ranging from equipment used to perform intricate genomic sequencing to reagents required for advanced laboratory experiments. Thus, Thermo Fisher sustains its financial health through a combination of one-time sales and recurring revenue streams, a strategy that not only reflects its adaptability but also ensures long-term profitability and market leadership in the ever-evolving landscape of scientific research.
See Also
What is Thermo Fisher Scientific Inc's Total Liabilities & Equity?
Total Liabilities & Equity
110.3B
USD
Based on the financial report for Dec 31, 2025, Thermo Fisher Scientific Inc's Total Liabilities & Equity amounts to 110.3B USD.
What is Thermo Fisher Scientific Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
10%
Over the last year, the Total Liabilities & Equity growth was 13%. The average annual Total Liabilities & Equity growth rates for Thermo Fisher Scientific Inc have been 4% over the past three years , 10% over the past five years , and 10% over the past ten years .